Agenus (NASDAQ:AGEN) Given New $7.00 Price Target at HC Wainwright

Agenus (NASDAQ:AGEN) had its price target dropped by investment analysts at HC Wainwright from $8.00 to $7.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has a “neutral” rating on the biotechnology company’s stock. HC Wainwright’s target price suggests a potential upside of 116.05% from the company’s previous close.

Several other brokerages have also recently issued reports on AGEN. Robert W. Baird cut Agenus from an “outperform” rating to a “neutral” rating and cut their price objective for the company from $35.00 to $8.00 in a research note on Friday, July 19th. StockNews.com cut Agenus from a “hold” rating to a “sell” rating in a research note on Monday, August 12th. B. Riley lowered their target price on shares of Agenus from $42.00 to $18.00 and set a “buy” rating for the company in a research note on Wednesday, August 14th. William Blair cut shares of Agenus from an “outperform” rating to a “market perform” rating in a report on Thursday, July 18th. Finally, Baird R W lowered shares of Agenus from a “strong-buy” rating to a “hold” rating in a report on Friday, July 19th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, Agenus has an average rating of “Hold” and a consensus target price of $10.00.

Agenus Price Performance

Agenus stock traded down $0.66 during midday trading on Tuesday, hitting $3.24. 672,054 shares of the stock were exchanged, compared to its average volume of 639,793. The company has a 50 day moving average price of $4.86 and a two-hundred day moving average price of $8.91. The firm has a market cap of $69.89 million, a P/E ratio of -0.29 and a beta of 1.39. Agenus has a 1 year low of $3.20 and a 1 year high of $19.69.

Hedge Funds Weigh In On Agenus

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Point72 DIFC Ltd acquired a new position in Agenus during the 2nd quarter worth $51,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Agenus during the second quarter valued at about $106,000. BNP Paribas Financial Markets lifted its holdings in Agenus by 81.3% in the first quarter. BNP Paribas Financial Markets now owns 188,414 shares of the biotechnology company’s stock worth $109,000 after purchasing an additional 84,477 shares during the period. Exchange Traded Concepts LLC grew its position in Agenus by 52.0% in the 3rd quarter. Exchange Traded Concepts LLC now owns 27,543 shares of the biotechnology company’s stock valued at $151,000 after buying an additional 9,422 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in Agenus by 52.4% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 357,915 shares of the biotechnology company’s stock valued at $208,000 after buying an additional 123,058 shares during the period. 61.46% of the stock is owned by institutional investors.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.